Investors are always looking for stocks that are poised to beat at earnings season and Arbutus Biopharma Corporation ABUS may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Arbutus Biopharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABUS in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 22 cents per share for ABUS, compared to a broader Zacks Consensus Estimate of a loss of 23 cents per share. This suggests that analysts have very recently bumped up their estimates for ABUS, giving the stock a Zacks Earnings ESP of +2.22% heading into earnings season.
Arbutus Biopharma Corporation Price and EPS Surprise
Arbutus Biopharma Corporation price-eps-surprise | Arbutus Biopharma Corporation Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that ABUS has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Arbutus Biopharma, and that a beat might be in the cards for the upcoming report.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research